Recruiting
Phase 3

Coenzyme Q10

Sponsor:

UCLA

Code:

NCT06515184

Conditions

Gulf War Syndrome

Persian Gulf Syndrome

Mitochondrial Disorder, Respiratory Chain

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

PharmaNord Bio-Quinone Active CoQ10 Gold 100mg

PharmaNord Placebo

PharmaNord Bio-Quinone Active CoQ10 Gold 100mg

Study Details

Brief summary:

The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.

Conditions

Gulf War Syndrome

Persian Gulf Syndrome

Mitochondrial Disorder, Respiratory Chain

Study ID

NCT06515184

Start date

Sep 13, 2024

Status verified date

Apr, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Meets both CDC and Kansas deployment and symptom inclusion criteria.
  • Does not have a disqualifying condition.
  • Able to travel to a local Quest facility for study blood draws.
  • Adequate internet access to allow ZoomPro visit participation and remote survey completion.
  • Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).
  • Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.

Exclusion Criteria:

  • Participating in another clinical trial.
  • Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.
  • On Coumadin/ warfarin.
  • Unable to participate for the required duration of the study.

Study Design

Enrollment

192 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: CoQ10 Arm 1

PharmaNord Ubiquinone 100mg/1x day

active comparator: CoQ10 Arm 2

PharmaNord Ubiquinone 100mg/3x day

placebo comparator: Placebo Arm

Placebo (made by PharmaNord, matches active treatment)

Interventions

PharmaNord Bio-Quinone Active CoQ10 Gold 100mg

Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.

Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.

PharmaNord Placebo

Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.

Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.

PharmaNord Bio-Quinone Active CoQ10 Gold 100mg

Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.

Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.

Primary outcome measure

  • Number of symptoms (out of 20 on the UCSD Symptom Score Survey) showing more favorable change (trend or effect) on active treatment vs. on placebo. [ Time Frame: 3.5 months ]

Central Contacts and Locations

Central contacts

Janis B Ritchie, BSN

858-558-4950jbritchie@ucsd.edu

Locations

UC San Diego

Recruiting

La Jolla, California, United States, 92093

Contacts

Janis B. Ritchie, BSN

858-558-4950golombresearch@ucsd.edu

Principal Investigator:

Beatrice A. Golomb, MD, PhD

More Information

Sponsor

University of California, San Diego

Last update posted

May 1, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Diego on 2026-05-01.